Stock Groups

EU drug regulator to announce results of Moderna booster shot review next week -Breaking


© Reuters. FILEPHOTO: A Moderna COVID-19-vaccination is seen in a clinic near Aschaffenburg as coronavirus continues to spread. This was on January 15, 2021. REUTERS/Kai Pfaffenbach

LONDON (Reuters), -The European Union Drug Regulator expects to publish the results of its investigation of Moderna (NASDAQ)’s COVID-19 booster vaccination and begin a rolling review next week of Merck’s antiviral medication molnupiravir. A senior official announced this on Thursday.

Marco Cavaleri is the head of bio-health threats and vaccines strategy of the European Medicines Agency (EMA). He stated that results from the Moderna boost shot will be released on October 25, in a briefing.

It was unclear if Russia would apply for the COVID one-dose vaccine, Sputnik Light, as well as for the two-dose Sputnik V shot.

Watchdog Pfizer BioNTech boosters were approved by the FDA on October 4. The agency recommended that anyone with weaker immune systems receive Moderna or a third Pfizer BioNTech shot.

The member states were free to determine if the booster should be given to the larger population.

Interim data from Merck showed that Merck’s antiviral experimental pill may reduce the chance of death or hospitalisation for patients most susceptible to severe COVID-19.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



Mike Robinson
Mike covers the financial, utilities and biotechnology sectors for Street Register. He has been writing about investment and personal finance topics for almost 12 years. Mike has an MBA in Finance from Wake Forest University.